The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Novel biomarkers and emerging therapies for sickle cell disease
Raffaella Colombatti, MD, PhD, University of Padova, Padova, Italy discusses the importance of taking a multi-omics approach for the diagnosis and treatment of sickle cell disease (SCD), namely using clinical, hematological, and genetic data, together with imaging data. Dr Colombatti comments on using artificial intelligence (AI) in order to explore novel biomarkers for SCD and using this data to optimize patient treatment and open an avenue for a personalized medicine approach. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
